At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 463 enrolled
Drug / intervention
Baricitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
In Brief
A Phase 3 clinical trial evaluating Baricitinib, Placebo, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 463 participants across 103 sites in 14 countries.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustria, Belgium, Brazil, Finland, France, Germany, Italy, Japan, Netherlands, Poland, Russia, Spain, Switzerland, United Kingdom
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMay 2018
Primary CompletionNov 2019
Study CompletionApr 2023
TodayJul 2026
First PostedFeb 9, 2018
Enrollment StartMay 15, 2018
Primary CompletionNov 25, 2019
Study CompletionApr 20, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.4 years ago
Interventions
Baricitinibdrug
Administered orally.
Placebodrug
Administered orally.
Topical corticosteroiddrug
Administered as standard-of-care.